Krystexxa Plus Methotrexate Approved for Uncontrolled Gout
The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in 152 adults with uncontrolled gout.
Gout
Uric Acid-Lowering Therapy May Increase Risk for CKD
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
SGLT2 Inhibitors Shown to Increase Uric Acid Excretion
Increased uric acid excretion could explain, at least in part, the renoprotective effects of SGLT2 inhibitors.
Gout Drug May Cut Mortality in Heart Failure Hospitalizations
In-hospital mortality rate lower for patients with acute heart failure exacerbation who received colchicine for gout flare
Colchicine May Lower Risk of CKD Progression
Colchicine, a plant-derived alkaloid, has a broad range of anti-inflammatory effects that interfere with neutrophil function, according to investigators.
March 2022: Drug Pipeline Updates
A review of regulatory and drug development status updates.
Pegloticase Plus Methotrexate Gets Priority Review for Uncontrolled Gout
The sBLA submission is supported by data from the phase 4 MIRROR trial.
Allopurinol Not Tied to Higher Mortality for Patients With Gout and CKD
Allopurinol initiation, achieving target serum urate levels, allopurinol dose escalation not associated with increased mortality
Horizon Seeks Approval of Pegloticase Plus Methotrexate for Uncontrolled Gout
The sBLA submission is supported by data from the phase 4 MIRROR trial.
Urate-Degrading Enzyme Fast Tracked for Hyperuricemia With Gout and CKD
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.
